Glucagon-like Peptide-1 Secretion Is Inhibited by Lysophosphatidic Acid.
L-cells
glucagon-like peptide 1
inflammation
lysophosphatidic acid
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
09 Apr 2022
09 Apr 2022
Historique:
received:
25
03
2022
revised:
07
04
2022
accepted:
08
04
2022
entrez:
23
4
2022
pubmed:
24
4
2022
medline:
27
4
2022
Statut:
epublish
Résumé
Glucagon-like peptide-1 (GLP-1) potentiates glucose-stimulated insulin secretion (GSIS). While dozens of compounds stimulate GLP-1 secretion, few inhibit. Reduced GLP-1 secretion and impaired GSIS occur in chronic inflammation. Lysophosphatidic acids (LPAs) are bioactive phospholipids elevated in inflammation. The aim of this study was to test whether LPA inhibits GLP-1 secretion in vitro and in vivo. GLUTag L-cells were treated with various LPA species, with or without LPA receptor (LPAR) antagonists, and media GLP-1 levels, cellular cyclic AMP and calcium ion concentrations, and DPP4 activity levels were analyzed. Mice were injected with LPA, with or without LPAR antagonists, and serum GLP-1 and DPP4 activity were measured. GLUTag GLP-1 secretion was decreased ~70-90% by various LPAs. GLUTag expression of
Identifiants
pubmed: 35456981
pii: ijms23084163
doi: 10.3390/ijms23084163
pmc: PMC9025735
pii:
doi:
Substances chimiques
Lysophospholipids
0
Receptors, Lysophosphatidic Acid
0
Glucagon-Like Peptide 1
89750-14-1
Cyclic AMP
E0399OZS9N
Dipeptidyl Peptidase 4
EC 3.4.14.5
Calcium
SY7Q814VUP
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Diabetes Canada
ID : NOD_OG-3-15-4933-RD
Organisme : Canada Foundation for Innovation
ID : 30259
Organisme : Government of Ontario
ID : ER16-12-162
Organisme : Natural Sciences and Engineering Research Council
ID : RGPIN-2019-05642
Organisme : Natural Sciences and Engineering Research Council
ID : RGPIN-2012-418213
Organisme : Natural Sciences and Engineering Research Council
ID : RGPAS-2019-00008
Références
Cancers (Basel). 2019 Sep 19;11(9):
pubmed: 31546918
J Pharmacol Exp Ther. 2011 Mar;336(3):693-700
pubmed: 21159750
Diabetologia. 2020 Feb;63(2):362-373
pubmed: 31796986
Bioorg Med Chem Lett. 2008 Feb 1;18(3):1037-41
pubmed: 18178086
Mol Metab. 2019 Dec;30:72-130
pubmed: 31767182
J Saudi Heart Assoc. 2018 Apr;30(2):113-121
pubmed: 29910582
Cancers (Basel). 2020 May 10;12(5):
pubmed: 32397679
Proc Natl Acad Sci U S A. 1992 Sep 15;89(18):8641-5
pubmed: 1326760
Biochim Biophys Acta. 2008 Sep;1781(9):513-8
pubmed: 18621144
Mol Endocrinol. 1996 Apr;10(4):342-55
pubmed: 8721980
Int J Obes (Lond). 2020 Jun;44(6):1254-1263
pubmed: 31965072
J Card Fail. 2006 Dec;12(9):694-9
pubmed: 17174230
Med Sci (Basel). 2019 Jul 24;7(8):
pubmed: 31344877
Front Physiol. 2020 Jan 29;10:1607
pubmed: 32063863
Br J Pharmacol. 2010 Sep;161(2):241-70
pubmed: 20735414
Br J Pharmacol. 2010 Aug;160(7):1699-713
pubmed: 20649573
Exp Cell Res. 2006 Jun 10;312(10):1899-908
pubmed: 16564043
Signal Transduct Target Ther. 2021 Feb 1;6(1):45
pubmed: 33526777
Diabetes. 2003 May;52(5):1147-54
pubmed: 12716745
Lipids Health Dis. 2017 Jul 21;16(1):140
pubmed: 28732508
Pharmacol Ther. 2019 Dec;204:107404
pubmed: 31472182
Curr Alzheimer Res. 2019;16(8):741-752
pubmed: 31518224
J Lipid Res. 2011 Jun;52(6):1247-1255
pubmed: 21421848
Regul Pept. 1996 Apr 9;62(1):29-35
pubmed: 8738879
Eur J Endocrinol. 2019 Nov;181(5):499-507
pubmed: 31437816
J Immunol. 2014 Feb 1;192(3):851-7
pubmed: 24443508
Hepatol Res. 2019 Oct;49(10):1136-1146
pubmed: 31144415
Front Physiol. 2017 Apr 27;8:266
pubmed: 28496416
Endocrinology. 2015 Nov;156(11):3950-60
pubmed: 26270730
Atherosclerosis. 2013 Jul;229(1):192-7
pubmed: 23664202
Prog Lipid Res. 2003 Nov;42(6):498-526
pubmed: 14559069
J Lipid Res. 2014 Jul;55(7):1192-214
pubmed: 24643338
Mol Cell Endocrinol. 2019 Apr 15;486:96-104
pubmed: 30853600
Ann N Y Acad Sci. 2020 Feb;1461(1):104-126
pubmed: 31392745
Genes Dev. 2021 Mar 1;35(5-6):307-328
pubmed: 33649162
BMJ Open Diabetes Res Care. 2020 Jan;8(1):
pubmed: 32049633
Biochem Biophys Res Commun. 2009 Dec 18;390(3):809-14
pubmed: 19836346
J Clin Endocrinol Metab. 2015 Apr;100(4):E616-22
pubmed: 25675385
Diabetologia. 2017 Aug;60(8):1442-1453
pubmed: 28526921
Diabetologia. 2004 May;47(5):806-15
pubmed: 15095038
Dan Med Bull. 2004 Nov;51(4):364-70
pubmed: 16009062
Physiol Rep. 2015 Sep;3(9):
pubmed: 26381015
Basic Clin Pharmacol Toxicol. 2004 Dec;95(6):252-62
pubmed: 15569269
Diabetes. 1989 Mar;38(3):338-42
pubmed: 2645190
Diabetes. 2002 Sep;51(9):2757-63
pubmed: 12196469
Am J Physiol Heart Circ Physiol. 2013 Feb 15;304(4):H538-46
pubmed: 23241323
Diabetologia. 2007 Oct;50(10):2181-9
pubmed: 17643200
Horm Metab Res. 2011 May;43(5):300-5
pubmed: 21360419
Horm Mol Biol Clin Investig. 2016 May 1;26(2):87-95
pubmed: 26953712
Diabetes. 2015 May;64(5):1513-21
pubmed: 25412624
Circulation. 2004 Mar 2;109(8):962-5
pubmed: 14981009
Neuropharmacology. 2020 Jan 1;162:107813
pubmed: 31628935
Mol Cell Endocrinol. 2019 Oct 1;496:110524
pubmed: 31362031
Int J Mol Sci. 2019 Jun 11;20(11):
pubmed: 31212704
Diabetologia. 2013 May;56(5):965-72
pubmed: 23377698
Front Immunol. 2016 Apr 22;7:154
pubmed: 27148273
Nat Med. 2005 Jan;11(1):90-4
pubmed: 15619630
Circulation. 2008 May 6;117(18):2340-50
pubmed: 18427132
Diabetologia. 2013 Jun;56(6):1394-402
pubmed: 23508306
J Physiol. 2012 Jun 15;590(12):2917-36
pubmed: 22495587
Diabetes Care. 2011 May;34 Suppl 2:S251-7
pubmed: 21525464
J Biochem. 2011 Sep;150(3):223-32
pubmed: 21746769
J Hypertens. 2020 Mar;38(3):377-386
pubmed: 31764586
Acta Diabetol. 2019 Apr;56(4):385-396
pubmed: 30519965
Lipids. 2017 May;52(5):457-461
pubmed: 28405875
J Biol Chem. 2003 Jan 3;278(1):471-8
pubmed: 12409292
Annu Rev Pharmacol Toxicol. 2010;50:157-86
pubmed: 20055701
Proc Natl Acad Sci U S A. 1987 May;84(10):3434-8
pubmed: 3033647
Diabetes. 2005 Feb;54(2):482-91
pubmed: 15677506
Endocrinology. 1991 Jun;128(6):3175-82
pubmed: 1674688
J Physiol Biochem. 2012 Dec;68(4):635-44
pubmed: 22644624